First clinical experiences with the Mcrpc Therapy in sequence doceaxel-cabazitaxel-enzalutamide for two workshops in the Czech Republic

Simple item page
dc.contributor.authorRichter Igorcs
dc.contributor.authorFilipenský P.cs
dc.contributor.authorRotnáglová S.cs
dc.contributor.authorSvobodová S.cs
dc.contributor.authorNovák R.cs
dc.date.accessioned2018-09-25T12:19:37Z
dc.date.available2018-09-25T12:19:37Z
dc.date.issued2017cs
dc.format.extent0cs
dc.identifier.urihttps://dspace.tul.cz/handle/15240/31985
dc.language.isoczecs
dc.relation.ispartofseries0cs
dc.subjectsequential treatmencs
dc.subjectmetastatic castrationally-resistant prostate cancercs
dc.subjecttreatment of docetaxel-cabazitaxel-enzalutamidecs
dc.titleFirst clinical experiences with the Mcrpc Therapy in sequence doceaxel-cabazitaxel-enzalutamide for two workshops in the Czech Republicen
dc.titlePrvní klinické zkušenosti s léčbou Mcrpc v sekvenci docetaxel-cabazitaxel-enzalutamid na dvou pracovištích v České republicecs
local.identifier.publikace5456
Files
Collections